PL353827A1 - Pochodne 8-fenylo-6, 9-dihydro-[1,2,4] triazolo [3Pochodne 8-fenylo-6, 9-dihydro-[1,2,4] triazolo [3,4-i]-puryn-5-onu,4-i]-puryn-5-onu - Google Patents

Pochodne 8-fenylo-6, 9-dihydro-[1,2,4] triazolo [3Pochodne 8-fenylo-6, 9-dihydro-[1,2,4] triazolo [3,4-i]-puryn-5-onu,4-i]-puryn-5-onu

Info

Publication number
PL353827A1
PL353827A1 PL00353827A PL35382700A PL353827A1 PL 353827 A1 PL353827 A1 PL 353827A1 PL 00353827 A PL00353827 A PL 00353827A PL 35382700 A PL35382700 A PL 35382700A PL 353827 A1 PL353827 A1 PL 353827A1
Authority
PL
Poland
Prior art keywords
triazolo
dihydro
phenyl
Prior art date
Application number
PL00353827A
Other languages
English (en)
Inventor
Ferrer JordiGracia Ferrer Jordi Gracia
Gras JoanFeixas Gras Joan Feixas
Soto Jose ManuelPrieto Soto Jose Manuel Prieto
Noverola ArmandoVega Noverola Armando Vega
Juan BernatVidal Juan Bernat Vidal
Original Assignee
Almirall Prodesfarma S.A.Almirall Prodesfarma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma S.A.Almirall Prodesfarma S.A. filed Critical Almirall Prodesfarma S.A.Almirall Prodesfarma S.A.
Publication of PL353827A1 publication Critical patent/PL353827A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL00353827A 1999-07-27 2000-07-24 Pochodne 8-fenylo-6, 9-dihydro-[1,2,4] triazolo [3Pochodne 8-fenylo-6, 9-dihydro-[1,2,4] triazolo [3,4-i]-puryn-5-onu,4-i]-puryn-5-onu PL353827A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009901694A ES2166270B1 (es) 1999-07-27 1999-07-27 Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
PCT/EP2000/007062 WO2001007441A1 (en) 1999-07-27 2000-07-24 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES

Publications (1)

Publication Number Publication Date
PL353827A1 true PL353827A1 (pl) 2003-12-01

Family

ID=8309393

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00353827A PL353827A1 (pl) 1999-07-27 2000-07-24 Pochodne 8-fenylo-6, 9-dihydro-[1,2,4] triazolo [3Pochodne 8-fenylo-6, 9-dihydro-[1,2,4] triazolo [3,4-i]-puryn-5-onu,4-i]-puryn-5-onu

Country Status (34)

Country Link
US (1) US7034016B2 (pl)
EP (1) EP1198464B1 (pl)
JP (1) JP2003505461A (pl)
KR (1) KR20020022786A (pl)
CN (1) CN1198825C (pl)
AR (1) AR024969A1 (pl)
AT (1) ATE251625T1 (pl)
AU (1) AU777571B2 (pl)
BG (1) BG106346A (pl)
BR (1) BR0012764A (pl)
CA (1) CA2380181A1 (pl)
CO (1) CO5190717A1 (pl)
CZ (1) CZ2002311A3 (pl)
DE (1) DE60005838T2 (pl)
DK (1) DK1198464T3 (pl)
EE (1) EE200200046A (pl)
ES (2) ES2166270B1 (pl)
HK (1) HK1044332B (pl)
HU (1) HUP0202103A3 (pl)
IL (1) IL147770A0 (pl)
MY (1) MY129590A (pl)
NO (1) NO20020391L (pl)
NZ (1) NZ516780A (pl)
PE (1) PE20010401A1 (pl)
PL (1) PL353827A1 (pl)
PT (1) PT1198464E (pl)
RU (1) RU2258705C2 (pl)
SK (1) SK1352002A3 (pl)
TR (1) TR200200785T2 (pl)
TW (1) TW568912B (pl)
UA (1) UA73513C2 (pl)
UY (1) UY26258A1 (pl)
WO (1) WO2001007441A1 (pl)
ZA (1) ZA200200561B (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE0300917D0 (sv) 2003-03-31 2003-03-31 St Jude Medical Multi-chamber pacing system
US20070010450A1 (en) 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
AU2005243192A1 (en) * 2004-04-29 2005-11-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006055573A2 (en) * 2004-11-18 2006-05-26 Schering Corporation Methods of using pde v inhibitors for the treatment of congestive heart failure
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CA2877146C (en) 2012-06-18 2020-10-20 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
IL275817B2 (en) * 2018-01-04 2024-04-01 Impetis Biosciences Ltd Tricyclic compounds, compositions and medicinal applications thereof
WO2020045558A1 (ja) * 2018-08-30 2020-03-05 テラ・ストーン株式会社 キサンチンオキシダーゼを阻害するためのヒドラジノプリン化合物及びトリアゾロプリン化合物
CN112225761B (zh) * 2020-12-16 2021-03-12 南京颐媛生物医学研究院有限公司 一种嘧啶并三氮唑及其合成方法
US20240092782A1 (en) * 2021-03-09 2024-03-21 Basf Se Tricyclic pesticidal compounds
CN116964055A (zh) * 2021-03-09 2023-10-27 巴斯夫欧洲公司 杀害虫的三环化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
DE3347290A1 (de) * 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
ATE145908T1 (de) * 1989-09-14 1996-12-15 Kyowa Hakko Kogyo Kk 5-triazolo(3,4-i)purinderivate
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
ZA914727B (en) * 1990-06-21 1992-03-25 Schering Corp Polycyclic guanine derivatives
WO1996026208A1 (en) * 1995-02-21 1996-08-29 Yamasa Corporation Purine compounds and xanthine oxidase inhibitors
SK285991B6 (sk) * 1997-04-25 2008-01-07 Pfizer Inc. Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze
AU4501199A (en) * 1998-06-03 1999-12-20 Almirall Prodesfarma S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
DE60130772T2 (de) * 2000-08-09 2008-07-17 Laboratorios Almirall, S.A. Pyrrolotriazolopyrimidinonderivate

Also Published As

Publication number Publication date
AR024969A1 (es) 2002-10-30
PE20010401A1 (es) 2001-04-16
HUP0202103A3 (en) 2004-12-28
IL147770A0 (en) 2002-08-14
TW568912B (en) 2004-01-01
DE60005838D1 (de) 2003-11-13
ES2166270B1 (es) 2003-04-01
ES2208378T3 (es) 2004-06-16
CO5190717A1 (es) 2002-08-29
UY26258A1 (es) 2000-12-29
NO20020391L (no) 2002-03-25
US20030060627A1 (en) 2003-03-27
DK1198464T3 (da) 2004-02-16
EP1198464A1 (en) 2002-04-24
ATE251625T1 (de) 2003-10-15
PT1198464E (pt) 2004-02-27
ZA200200561B (en) 2003-06-25
DE60005838T2 (de) 2004-08-19
TR200200785T2 (tr) 2002-09-23
EE200200046A (et) 2003-04-15
BR0012764A (pt) 2002-07-02
WO2001007441A1 (en) 2001-02-01
ES2166270A1 (es) 2002-04-01
RU2258705C2 (ru) 2005-08-20
BG106346A (en) 2002-09-30
UA73513C2 (en) 2005-08-15
CA2380181A1 (en) 2001-02-01
JP2003505461A (ja) 2003-02-12
HK1044332A1 (en) 2002-10-18
CZ2002311A3 (cs) 2003-01-15
EP1198464B1 (en) 2003-10-08
CN1374962A (zh) 2002-10-16
HK1044332B (en) 2004-10-15
CN1198825C (zh) 2005-04-27
MY129590A (en) 2007-04-30
SK1352002A3 (en) 2003-04-01
NZ516780A (en) 2004-01-30
AU6277200A (en) 2001-02-13
NO20020391D0 (no) 2002-01-25
KR20020022786A (ko) 2002-03-27
AU777571B2 (en) 2004-10-21
HUP0202103A2 (en) 2002-10-28
US7034016B2 (en) 2006-04-25

Similar Documents

Publication Publication Date Title
IL147770A0 (en) 8-phenyl-6,9-dihydro-[1,2,4] triazolo[3,4-i] purin-5-one derivatives
TW526820U (en) Seat
PL349341A1 (en) Imidazo[4,5-c]-pyridine-4-on-derivatives
GB9927175D0 (en) Wheel chairs
AU142241S (en) Tire
SI1198464T1 (en) 8-PHENYL-6,9-DIHYDRO-(1,2,4)TRIAZOLO(3,4-i)PURIN-5-ONE DERIVATIVES
PL352760A1 (pl) Oksatiepino [6,5-b] dihydropirydyny, zawierające je kompozycje oraz sposoby wytwarzania
TW380533U (en) Caster
CA87281S (en) Shower-batch seat
GB2352622B (en) Seat
CA87453S (en) Tire
CA87508S (en) Tire
CA87026S (en) Tire
CA87343S (en) Tire
CA86115S (en) Tire
CA85958S (en) Tire
CA88020S (en) Tire
CA88014S (en) Tire
CA87152S (en) Tire
CA87456S (en) Tire
CA88015S (en) Tire
CA87964S (en) Tire
CA87717S (en) Tire
CA87972S (en) Tire
CA87924S (en) Tire

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)